Future perspectives in specific immunotherapy of melanoma.
With the discovery of T-cell recognised tumour-associated antigens (TAAs), interest in specific immunotherapy for treatment of malignancies has increased substantially. The majority of studies investigating TAAs have focused on melanoma-associated antigens because of evidence that the immune system influences the pathogenesis of melanoma. This paper reviews the different types of melanoma antigens, their in vitro and in vivo immunogenicity and clinical data regarding the use of specific immunotherapy in patients with stage I-IV melanoma. Results of clinical studies are highly variable but encourage further research in these patients. Developing and perfecting laboratory and clinical correlates of response to these specific immunotherapies are vital to determining their role in clinical practice.
Parmiani
G
G
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
D000951:Antigens, Neoplasm / Q000032:analysis; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines